These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2564495)

  • 1. Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes.
    Barker R; Duncan J; Lees A
    Lancet; 1989 Mar; 1(8639):675. PubMed ID: 2564495
    [No Abstract]   [Full Text] [Related]  

  • 2. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
    Hughes AJ; Lees AJ; Stern GM
    Lancet; 1990 Jul; 336(8706):32-4. PubMed ID: 1973218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The apomorphine test for diagnosis of parkinsonian syndrome].
    Piccini P; Del Dotto P; Napolitano A; Pardini C; Bonuccelli U
    Riv Neurol; 1990; 60(6):221-3. PubMed ID: 2100046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apomorphine test for dopaminergic responsiveness.
    Lancet; 1989 Jun; 1(8649):1262-3. PubMed ID: 2566801
    [No Abstract]   [Full Text] [Related]  

  • 5. [Apomorphine as adjuvant treatment in idiopathic Parkinson syndrome].
    Bösch MF; Ludin HP
    Schweiz Arch Neurol Psychiatr (1985); 1994; 145(5):8-13. PubMed ID: 7709189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The apomorphine test in parkinsonian syndromes.
    D'Costa DF; Abbott RJ; Pye IF; Millac PA
    J Neurol Neurosurg Psychiatry; 1991 Oct; 54(10):870-2. PubMed ID: 1744640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apomorphine test in parkinsonian syndromes.
    Rascol O; Senard JM; Rascol A; Montastruc JL
    Lancet; 1990 Aug; 336(8713):518. PubMed ID: 1975034
    [No Abstract]   [Full Text] [Related]  

  • 9. [The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience].
    Roth J; Růzicka E; Mecír P
    Cas Lek Cesk; 1994 Nov; 133(21):665-7. PubMed ID: 7805088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.
    Ray-Chaudhuri K; Abbott RJ; Millac PA
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):372-3. PubMed ID: 2056329
    [No Abstract]   [Full Text] [Related]  

  • 11. [The diagnosis of the parkinsonian syndrome].
    Möller JC; Pogarell O; Oertel WH
    Dtsch Med Wochenschr; 1999 Feb; 124(7):193-6. PubMed ID: 10093579
    [No Abstract]   [Full Text] [Related]  

  • 12. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
    Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
    Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease.
    Grandas F; Gancher S; Lera G; Rodriguez M; Woodward WR; Nutt J; Obeso JA
    Neurology; 1992 Jul; 42(7):1287-90. PubMed ID: 1620335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The motor response to sequential apomorphine in parkinsonian fluctuations.
    Hughes AJ; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):358-60. PubMed ID: 2056323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations.
    Stibe C; Lees A; Stern G
    Lancet; 1987 Apr; 1(8537):871. PubMed ID: 2882282
    [No Abstract]   [Full Text] [Related]  

  • 17. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
    Papuć E; Trzciniecka O; Rejdak K
    Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease.
    Garcia Ruiz PJ
    Mov Disord; 2006 May; 21(5):727-8. PubMed ID: 16547919
    [No Abstract]   [Full Text] [Related]  

  • 20. Subcutaneous apomorphine in the treatment of Parkinson's disease.
    Frankel JP; Lees AJ; Kempster PA; Stern GM
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):96-101. PubMed ID: 2313313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.